print_label | resize_label

AS YOU INDIVIDUALIZE TREATMENT FOR YOUR APPROPRIATE ADULT PATIENTS WITH TYPE 2 DIABETES

KOMBIGLYZE XR demonstrated significant A1C reductions and lower rates of hypoglycemia in treatment-naïve patients.*

VIEW DATA

KOMBIGLYZE XR demonstrated significant A1C reductions and lower rates of hypoglycemia in treatment-naïve patients.*

VIEW DATA

*Reported hypoglycemia over 24-week study for treatment-naïve patients was 3.4% for saxagliptin 5 mg + metformin IR [n=320] vs 4.0% for placebo + metformin IR [n=328].1,2